The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfu...
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
About this item
Full title
Author / Creator
Oelze, Matthias , Kröller-Schön, Swenja , Welschof, Philipp , Jansen, Thomas , Hausding, Michael , Mikhed, Yuliya , Stamm, Paul , Mader, Michael , Zinßius, Elena , Agdauletova, Saule , Gottschlich, Anna , Steven, Sebastian , Schulz, Eberhard , Bottari, Serge P. , Mayoux, Eric , Münzel, Thomas and Daiber, Andreas
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether...
Alternative Titles
Full title
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_1625577213
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1625577213
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0112394
